重组人血管内皮抑制素致中毒性表皮坏死松解症  

Recombinant human endostatin‑induced toxic epidermal necrolysis

作　　者：李进峰[1] 侯佳[1] 苗小金 王泉[1] 李丰军[3] 张媛[1] Li Jinfeng;Hou Jia;Miao Xiaojin;Wang Quan;Li Fengjun;Zhang Yuan(Department of Pharmacy,Weihai Municipal Hospital,Shandong Province,Weihai 264299,China;Department of Dermatology,Weihai Municipal Hospital,Shandong Province,Weihai 264299,China;Department of Traditional Chinese Medicine,Weihai Municipal Hospital,Shandong Province,Weihai 264299,China)

机构地区：[1]威海市立医院药剂科,威海264299 [2]威海市立医院皮肤科,威海264299 [3]威海市立医院中医科,威海264299

出　　处：《药物不良反应杂志》2022年第3期166-168,共3页Adverse Drug Reactions Journal

摘　　要：1例59岁男性患者因肺低分化腺癌伴脑转移给予靶向药物重组人血管内皮抑制素注射液15 mg静脉滴注、1次/d,连续14 d。停药第17天,患者颈部和胸部出现红斑、瘙痒,随后红斑迅速扩散至全身,并出现水疱和广泛的表皮脱落,伴有瘙痒、疼痛和低热。考虑为重组人血管内皮抑制素导致的中毒性表皮坏死松解症。给予大剂量糖皮质激素和人免疫球蛋白治疗,2周后,皮损基本愈合。A 59‑year‑old male patient received targeted drug recombinant human endostatin injection 15 mg intravenously once daily for 14 days for poorly differentiated adenocarcinoma of lung with brain metastasis.On the 17th day after drug withdrawal,erythema and pruritus appeared on the neck and chest,and then the erythema quickly spread to the whole body,with blisters and extensive epidermal exfoliation,accompanied by pruritus,pain,and mild fever.Toxic epidermal necrolysis caused by recombinant human endostatin was considered.High‑dose of glucocorticoid and human immunoglobulin were given and 2 weeks later,the skin lesions healed basically.

关 键 词：内皮抑素类 表皮坏死松解症 中毒性 

分 类 号：R969.3[医药卫生—药理学]